Drug intelligence / Profile preview

Shigella flexneri 2a InvaplexAR

Development stage: Phase 1
Lead developer: Walter Reed Army Institute of Research
Modality: Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

Shigella flexneri 2a InvaplexAR is an artificial Invaplex vaccine, developed as a subunit approach, designed to prevent Shigellosis and Bacillary Dysentery. It induces immune responses against serotype-specific lipopolysaccharide (LPS) and conserved invasion plasmid antigen (Ipa) proteins B and C of Shigella flexneri 2a. The vaccine is administered intranasally and has completed a Phase 1 clinical trial to assess its safety and immunogenicity.

Targets

S. flexneri 2a LPS (Shigella flexneri serotype 2a lipopolysaccharide)IpaB (Invasion plasmid antigen B)IpaC (Invasion plasmid antigen C)

Beyond the preview

Go deeper on Shigella flexneri 2a InvaplexAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shigella flexneri 2a InvaplexAR.

Explore the full profile